Elina Gregoriou1, Ioannis Mamais2, Irene Tzanetakou3, Giagkos Lavranos4, Stavri Chrysostomou5. 1. Department of Life Sciences, European University Cyprus, Engomi, 1516 Nicosia-Cyprus. 2. Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Greece. 3. Department of Life Sciences, European University of Cyprus, Nicosia, Cyprus, Engomi, 1516 Nicosia-Cyprus. 4. Department of Health Sciences, European University Cyprus, Engomi, 1516 Nicosia-Cyprus. 5. Department of Life Sciences, School of Science, European University Cyprus, Engomi, 1516 Nicosia-Cyprus.
Abstract
AIM: The aim of this study was to examine the effects of vitamin D supplementation in patients newly diagnosed with type 1 diabetes (T1D) assessed by insulin needs and changes in glycemic indices, as evidenced by randomized controlled trials (RCTs). METHODS: A total of 7 RCTs were retrieved from PubMed/Medline and EBSCO databases by MeSH term search, and were reviewed systematically. The RCTs included examined the effects of alphacalcidole (n = 2), cholecalciferol (n = 2), and calcitriol (n = 3) supplementation on changes in daily insulin dose (DID), fasting Cpeptide (FCP), stimulated C-peptide (SCP), and HbA1c. In total, 287 individuals, diagnosed with T1D within a period of 4 weeks to 1 year and aged between 5 to 38 years, were examined. RESULTS: Significant positive effects on DID, FCP, and SCP levels were observed after supplementation with alphacalcidole and cholecalciferol, whereas supplementation with calcitriol showed no effect. CONCLUSIONS: Vitamin D supplementation in the form of alphacalcidole and cholecalciferol appears to be beneficial in the treatment of T1D patients by attenuating the natural history of the disease.
AIM: The aim of this study was to examine the effects of vitamin D supplementation in patients newly diagnosed with type 1 diabetes (T1D) assessed by insulin needs and changes in glycemic indices, as evidenced by randomized controlled trials (RCTs). METHODS: A total of 7 RCTs were retrieved from PubMed/Medline and EBSCO databases by MeSH term search, and were reviewed systematically. The RCTs included examined the effects of alphacalcidole (n = 2), cholecalciferol (n = 2), and calcitriol (n = 3) supplementation on changes in daily insulin dose (DID), fasting Cpeptide (FCP), stimulated C-peptide (SCP), and HbA1c. In total, 287 individuals, diagnosed with T1D within a period of 4 weeks to 1 year and aged between 5 to 38 years, were examined. RESULTS: Significant positive effects on DID, FCP, and SCP levels were observed after supplementation with alphacalcidole and cholecalciferol, whereas supplementation with calcitriol showed no effect. CONCLUSIONS:Vitamin D supplementation in the form of alphacalcidole and cholecalciferol appears to be beneficial in the treatment of T1D patients by attenuating the natural history of the disease.
Authors: D Pitocco; A Crinò; E Di Stasio; S Manfrini; C Guglielmi; S Spera; G Beretta Anguissola; N Visalli; C Suraci; M C Matteoli; I P Patera; M G Cavallo; C Bizzarri; P Pozzilli Journal: Diabet Med Date: 2006-08 Impact factor: 4.359
Authors: Marco Infante; Camillo Ricordi; Janine Sanchez; Michael J Clare-Salzler; Nathalia Padilla; Virginia Fuenmayor; Carmen Chavez; Ana Alvarez; David Baidal; Rodolfo Alejandro; Massimiliano Caprio; Andrea Fabbri Journal: Nutrients Date: 2019-09-11 Impact factor: 5.717
Authors: Wentong Long; Mohammad Fatehi; Shubham Soni; Rashmi Panigrahi; Koenraad Philippaert; Yi Yu; Rees Kelly; Brett Boonen; Amy Barr; Dominic Golec; Scott A Campbell; Katarina Ondrusova; Matt Hubert; Troy Baldwin; M Joanne Lemieux; Peter E Light Journal: J Physiol Date: 2020-08-13 Impact factor: 5.182
Authors: Friederike Maretzke; Angela Bechthold; Sarah Egert; Jana B Ernst; Debora Melo van Lent; Stefan Pilz; Jörg Reichrath; Gabriele I Stangl; Peter Stehle; Dorothee Volkert; Michael Wagner; Julia Waizenegger; Armin Zittermann; Jakob Linseisen Journal: Nutrients Date: 2020-03-31 Impact factor: 5.717